Clinical Research Directory

Inclusion Criteria: * Patients with spondyloarthritis validating ASAS or modified New York criteria for which adalimumab treatment is indicated, and performing the pre-biotherapy assessment; * Between 18 and 70 years old; * Biotherapy naive; * Who can be regularly monitored for 6 months; * Able to take all the treatment; * Effective contraception for patients of childbearing age (oral contraceptive, intrauterine device, implant, spermicide, surgical sterilization or abstinence) during the study and at least for 5 months after the last injection; * Able to read and understand the terms of the protocol; * Having dated and signed the informed consent form of the trial; * Affiliated to a social security scheme. Exclusion Criteria: * Patients having a contraindication to an anti-TNF; * Surgical operation scheduled during the trial; * Having difficulty understanding the French language; * Having impaired upper functions (dementia of Alzheimer type, etc...); * Psycho-social instability incompatible with regular follow-up (homeless, addictive behavior, history of psychiatric pathology or any other comorbidity which would make a free and informed consent impossible or limit adherence to the protocol); * Having previously received a biotherapy. There is no other exclusion criteria taking into account prior therapies and the duration of these therapies; * Described in articles L.1121-5 to L.1121-8 of the Personal Status Code: pregnant, parturient and nursing women; persons in detention by judicial or administrative decision; adults subject to a legal protection order; * Already participating in interventional research.